It's hard to make any judgements on that with such a small sample (4 patients with each chemo combo). What was clear was that Bavi/chemo combo achieved much better results than what would have been expected with cheom alone. Another consideration re: Docetaxel in those particular patients- it may be the case that Docetaxel, being one of the "tougher" chemos to deal with, (and the toughest of the three used in that trial) may have been hard for those particular patients to bear with such wrecked immune systems after having been through 4 or so rounds of chemo treatment and with such advanced disease.
What we do know is that Docetaxel had the best preclinical data, and that the combo is now going into much stronger patients.
A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice
By the way - speaking of time frames, that first Bavi/Docetaxel paper was published in May 2005. It's pretty nice to see Bavi/Docetaxel go from experimental mouse paper to the middle of phase II clinical trials in the course of 3 yrs :)
Hey - speaking of Bavi/Docetaxel - check out these charts of the combo against tumors, as well as PICS OF THE COMBO AGAINST METASTATIC growth -
Figure 3. Enhanced inhibition of orthotopic human breast tumors by 3G4 plus docetaxel. Four groups of 10 mice bearing orthotopic MDA-MB-435 human breast tumors were treated 6 days after tumor cell injection with biweekly i.p. injections of 3G4 (100 µg), docetaxel (5 or 10 mg/kg), and the combination of 3G4 (100 µg) plus docetaxel (5 or 10 mg/kg). Another group of mice received the control antibody, BBG3 (100 µg). Treatments were continued for 3 weeks. Tumor volumes were measured twice weekly and the body weights of the mice were recorded regularly. A, effects on tumor growth. The combination therapy was significantly more effective than either agent alone. Tumor growth in BBG3 recipients was indistinguishable from that in untreated mice in multiple experiments (result not shown). Points, mean tumor volumes in groups of mice; bars, SE. B, lack of effect of 3G4 on toxicity-dependent weight loss caused by docetaxel. The 3G4-treated group gained weight at the same rate as the control BBG3-treated group. Animals treated with docetaxel (10 mg/kg, biweekly) experienced a marked (~20%) body weight loss but regained weight after treatment was stopped on day 28. There is no significant difference in weight changes between the groups of mice treated with the combination versus docetaxel alone. Points, average body weights (g).
Figure 4. Enhanced inhibition of the establishment and growth of human breast tumors in the lungs of mice treated with 3G4 plus docetaxel. Nu/nu mice were injected i.v. with 1 x 106 MDA-MB-435 human breast tumor cells into a tail vein. Treatment with 3G4 and/or docetaxel began 5 days after tumor cell injection. The number of tumor colonies in the lungs was determined on day 56. The number of surface tumor colonies was counted for 10 mice from each group and the average was calculated. Columns, mean; bars, SE. The numbers in parentheses are the number of mice in each group that developed tumor colonies on the surface of their lungs. Representative pictures of the lungs are shown. In mice treated with control antibody BBG 3, many large tumor colonies were seen on the surface of the lungs. In the 3G4 and docetaxel groups, relatively few, small colonies were observed. Yet, fewer and smaller colonies or no colonies at all were seen in the combination group. Individually, 3G4 and docetaxel significantly inhibited the formation and growth of pulmonary tumor colonies (*P < 0.05, compared with control). The combination therapy was significantly more effective than either single agent alone (**P < 0.05, compared with single agent).
News 
Market Data 
Discover 
AI
